| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0049-3848(02)00145-7 |
| P698 | PubMed publication ID | 12379286 |
| P2093 | author name string | Peter Hellstern | |
| Hannelore Haubelt | |||
| P2860 | cites work | Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination | Q31846261 |
| Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome | Q33333765 | ||
| Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? | Q33333811 | ||
| Von Willebrand factor--cleaving protease activity in congenital thrombotic thrombocytopenic purpura | Q33335798 | ||
| SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available | Q33504054 | ||
| Inactivation of viruses in fresh-frozen plasma | Q40800788 | ||
| Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery | Q42670512 | ||
| Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). | Q45732764 | ||
| Clinical tolerance of methylene blue virus-inactivated plasma. A randomized crossover trial in 12 healthy human volunteers | Q45743827 | ||
| Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation | Q45785927 | ||
| Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. | Q50507853 | ||
| Inactivation of viruses in human plasma. | Q50510564 | ||
| Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. | Q50517766 | ||
| The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. | Q50770247 | ||
| Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. | Q50876391 | ||
| A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. | Q53340662 | ||
| Manufacture and in vitro characterization of a solvent/detergent-treated human plasma | Q67591598 | ||
| Freezing of plasma and recovery of factor VIII | Q70279113 | ||
| Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half-strength citrate anticoagulant | Q70357481 | ||
| Effect of citrate anticoagulants on factor VIII levels in plasma | Q70388206 | ||
| Activation of plasma components by leukocyte removal filters | Q70884693 | ||
| Prestorage leukocyte depletion with in-line filtration of whole blood in comparison with blood component leukocyte depletion | Q70944110 | ||
| Preparation of improved cryoprecipitated factor VIII concentrate. A controlled study of three variables affecting the yield | Q71516789 | ||
| Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant | Q71690975 | ||
| Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders | Q72553172 | ||
| Coagulation factor levels in solvent/detergent-treated plasma | Q73110224 | ||
| The influence of citrate concentration on the quality of plasma obtained by automated plasmapheresis: a prospective study | Q73287824 | ||
| Specific determination of plasmin inhibitor activity in plasma: documentation of specificity of manual and automated procedures | Q73356711 | ||
| Viral safety of solvent/detergent-treated plasma | Q73378230 | ||
| Prestorage leukocyte reduction with in-line filtration of whole blood: evaluation of red cells and plasma storage | Q73619685 | ||
| Prestorage inline filtration of whole blood for obtaining white cell-reduced blood components | Q73839036 | ||
| Quality of fresh-frozen plasma during storage | Q73961370 | ||
| Efficacy of SD-treated plasma during liver transplantation | Q74105725 | ||
| The effect of leucocyte depletion on the quality of fresh-frozen plasma | Q74263433 | ||
| Improved blood preservation with 0.5CPD erythro-sol. Coagulation factor VIII activity and erythrocyte quality after delayed separation of blood | Q74573593 | ||
| In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma | Q77467530 | ||
| Hemovigilance: clinical tolerance of solvent-detergent treated plasma | Q77467551 | ||
| Current status of solvent/detergent-treated frozen plasma, whole-blood inline filtration, and Creutzfeldt-Jakob disease | Q77909823 | ||
| P921 | main subject | fresh frozen plasma | Q1225698 |
| P304 | page(s) | S3-8 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | Thrombosis Research | Q15758741 |
| P1476 | title | Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy | |
| P478 | volume | 107 Suppl 1 |
| Q83232961 | 4 Plasma for Therapeutic Use |
| Q50473987 | A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. |
| Q39062310 | A biochemical quality study of a pharmaceutically licenced coagulation active plasma (Octaplas) thawed by the SAHARA-III dry tempering system compared to the regular use of a water bath |
| Q30441694 | A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura |
| Q37119689 | A study of the quantity of some stable and labile coagulation factors in fresh-frozen plasma produced from whole blood stored for 24 hours in Iran |
| Q33368173 | Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light |
| Q45979592 | Coagulation profile of liquid-state plasma. |
| Q30355737 | Comparative lytic efficacy of rt-PA and ultrasound in porcine versus human clots |
| Q33360121 | Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura |
| Q33376161 | Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura |
| Q34038164 | Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience |
| Q40284794 | Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products |
| Q37201179 | Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma? |
| Q35874051 | Levels of factor VIII and factor IX in fresh-frozen plasma produced from whole blood stored at 4 °C overnight in Turkey |
| Q33374478 | Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development |
| Q89364437 | Nurses best practices for the management of thrombotic thrombocytopenic purpura |
| Q50787426 | Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C. |
| Q50791013 | Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18°C. |
| Q37209117 | Recommendations for the transfusion of plasma and platelets |
| Q37062415 | Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma |
| Q81306376 | Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing |
| Q24614152 | The influence of riboflavin photochemistry on plasma coagulation factors |
| Q50462990 | Thrombin generation capacity is impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergent-treated plasma (Octaplas) and a development product (Uniplas). |
| Q35040142 | Universal pathogen-reduced plasma in elective open-heart surgery and liver resection |
| Q36578184 | Update on pathogen reduction technology for therapeutic plasma: an overview |
| Q36874269 | Virus-inactivated plasma - Plasmasafe: a one-year experience |
| Q83808031 | [Techniques of preparation and indications of labile blood products] |
Search more.